메뉴 건너뛰기




Volumn 55, Issue 6, 2005, Pages 234-238

FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: Single centre study

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; VIDARABINE;

EID: 23044451425     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (7)

References (25)
  • 1
    • 0027213870 scopus 로고
    • Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia
    • Estey E, Plunkett W, Gandhi V, Rios M, Kantarjian H, Keating M. Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993; 9:343-50.
    • (1993) Leuk Lymphoma , vol.9 , pp. 343-350
    • Estey, E.1    Plunkett, W.2    Gandhi, V.3    Rios, M.4    Kantarjian, H.5    Keating, M.6
  • 2
    • 85087577492 scopus 로고    scopus 로고
    • Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid and /or granulocyte-colony stimulating factor in poor prognosis newly-diagnosed acute myeloid leukaemia and myelodysplastic syndrome
    • Estay EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid and /or granulocyte-colony stimulating factor in poor prognosis newly-diagnosed acute myeloid leukaemia and myelodysplastic syndrome. Blood 1999; 93:278-84.
    • (1999) Blood , vol.93 , pp. 278-284
    • Estay, E.H.1    Thall, P.F.2    Pierce, S.3    Cortes, J.4    Beran, M.5    Kantarjian, H.6
  • 3
    • 0028344644 scopus 로고
    • Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes; comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor
    • Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes; comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12:671-8.
    • (1994) J Clin Oncol , vol.12 , pp. 671-678
    • Estey, E.1    Thall, P.2    Andreeff, M.3    Beran, M.4    Kantarjian, H.5    O'Brien, S.6
  • 4
    • 0028104171 scopus 로고
    • FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias
    • Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 1994; 8:1842-6.
    • (1994) Leukemia , vol.8 , pp. 1842-1846
    • Visani, G.1    Tosi, P.2    Zinzani, P.L.3    Manfroi, S.4    Ottaviani, E.5    Testoni, N.6
  • 5
    • 0030326145 scopus 로고    scopus 로고
    • High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
    • Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81:513-20.
    • (1996) Haematologica , vol.81 , pp. 513-520
    • Clavio, M.1    Carrara, P.2    Miglino, M.3    Pierri, I.4    Canepa, L.5    Balleari, E.6
  • 6
    • 6844237007 scopus 로고    scopus 로고
    • Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia
    • Parker JE, Paglivca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99:939-44.
    • (1997) Br J Haematol , vol.99 , pp. 939-944
    • Parker, J.E.1    Paglivca, A.2    Mijovic, A.3    Cullis, J.O.4    Czepulkowski, B.5    Rassam, S.M.6
  • 7
  • 8
    • 0031812317 scopus 로고    scopus 로고
    • IDA-Flag (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission - induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a Phase- II trial
    • Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-Flag (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission - induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a Phase- II trial. Br J Haematol 1998; 102:647-55.
    • (1998) Br J Haematol , vol.102 , pp. 647-655
    • Fleischhack, G.1    Hasan, C.2    Graf, N.3    Mann, G.4    Bode, U.5
  • 9
    • 0033571328 scopus 로고    scopus 로고
    • Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes
    • Ferrara F, Leoni F, Pinto A, Mirto S, Morra E, Zagonel V, et al. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 1999; 86:2006-13.
    • (1999) Cancer , vol.86 , pp. 2006-2013
    • Ferrara, F.1    Leoni, F.2    Pinto, A.3    Mirto, S.4    Morra, E.5    Zagonel, V.6
  • 10
    • 0032836387 scopus 로고    scopus 로고
    • Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML
    • Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML. Ann Haematol 1999; 78:418-25.
    • (1999) Ann Haematol , vol.78 , pp. 418-425
    • Steinmetz, H.T.1    Schulz, A.2    Staib, P.3    Scheid, C.4    Glasmacher, A.5    Neufang, A.6
  • 11
    • 0023854422 scopus 로고
    • Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells
    • Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988; 48:329-34.
    • (1988) Cancer Res , vol.48 , pp. 329-334
    • Gandhi, V.1    Plunkett, W.2
  • 12
    • 0027450455 scopus 로고
    • Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy
    • Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11:116-24.
    • (1993) J Clin Oncol , vol.11 , pp. 116-124
    • Gandhi, V.1    Estey, E.2    Keating, M.J.3    Plunkett, W.4
  • 13
    • 0025643306 scopus 로고
    • Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro
    • Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4:826-34.
    • (1990) Leukemia , vol.4 , pp. 826-834
    • Tafuri, A.1    Andreeff, M.2
  • 14
    • 0028568321 scopus 로고
    • Fludarabine+Ara-C +G-CSF: Cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells
    • Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani PI, Tura S. Fludarabine+Ara-C +G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8:2076-82.
    • (1994) Leukemia , vol.8 , pp. 2076-2082
    • Tosi, P.1    Visani, G.2    Ottaviani, E.3    Manfroi, S.4    Zinzani, P.I.5    Tura, S.6
  • 15
    • 0031005627 scopus 로고    scopus 로고
    • Acute myeloid keukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group Study
    • Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovac ML, Chen IM, et al. Acute myeloid keukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group Study. Blood 1997; 89:3323-9.
    • (1997) Blood , vol.89 , pp. 3323-3329
    • Leith, C.P.1    Kopecky, K.J.2    Godwin, J.3    McConnell, T.4    Slovac, M.L.5    Chen, I.M.6
  • 16
    • 0025915728 scopus 로고
    • Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission
    • Horowitz MM, Messerer D, Hoelzer D. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991; 115:13-18.
    • (1991) Ann Intern Med , vol.115 , pp. 13-18
    • Horowitz, M.M.1    Messerer, D.2    Hoelzer, D.3
  • 17
    • 0026754295 scopus 로고
    • Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy
    • Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80:1090-3.
    • (1992) Blood , vol.80 , pp. 1090-1093
    • Biggs, J.C.1    Horowitz, M.M.2    Gale, R.P.3    Ash, R.C.4    Atkinson, K.5    Helbig, W.6
  • 18
    • 0036244526 scopus 로고    scopus 로고
    • Acute myeloid leukemia: Treatment of adults under 60 years
    • Burnett AK. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol 2002; 6:26-45.
    • (2002) Rev Clin Exp Hematol , vol.6 , pp. 26-45
    • Burnett, A.K.1
  • 19
    • 0346433669 scopus 로고    scopus 로고
    • Fludarabine cytosine arabinoside, granulocyte colony factor with or with out idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes
    • Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, et al. Fludarabine cytosine arabinoside, granulocyte colony factor with or with out idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 2004; 124:26-32.
    • (2004) Br J Haematol , vol.124 , pp. 26-32
    • Virchis, A.1    Koh, M.2    Rankin, P.3    Mehta, A.4    Potter, M.5    Hoffbrand, A.V.6
  • 20
    • 0038180704 scopus 로고    scopus 로고
    • FLAG-Ida in the treatment of refractory/relapsed acute myeloid leukemia: Single - Centre experience
    • Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-Ida in the treatment of refractory/relapsed acute myeloid leukemia: single - centre experience. Ann Hematol 2003; 82:231-5.
    • (2003) Ann Hematol , vol.82 , pp. 231-235
    • Pastore, D.1    Specchia, G.2    Carluccio, P.3    Liso, A.4    Mestice, A.5    Rizzi, R.6
  • 21
    • 0036994363 scopus 로고    scopus 로고
    • Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients
    • Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, et al. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients. J Exp Clin Cancer Res 2002; 21:482-7.
    • (2002) J Exp Clin Cancer Res , vol.21 , pp. 482-487
    • Clavio, M.1    Gatto, S.2    Beltrami, G.3    Quintino, S.4    Canepa, L.5    Pierri, I.6
  • 22
    • 0035035504 scopus 로고    scopus 로고
    • First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia
    • Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pieri I, et al. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia. Leuk Lymphoma 2001; 40:305-13.
    • (2001) Leuk Lymphoma , vol.40 , pp. 305-313
    • Clavio, M.1    Gatto, S.2    Beltrami, G.3    Cerri, R.4    Carrara, P.5    Pieri, I.6
  • 23
    • 10744230708 scopus 로고    scopus 로고
    • A feasibility study of simultaneous administration of gemtozumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
    • Kell WJ, Burnett AK, Chopra R, Yin JAL, Clark RE, Rohatiner A et al. A feasibility study of simultaneous administration of gemtozumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood 2003; 102:4277-83.
    • (2003) Blood , vol.102 , pp. 4277-4283
    • Kell, W.J.1    Burnett, A.K.2    Chopra, R.3    Yin, J.A.L.4    Clark, R.E.5    Rohatiner, A.6
  • 24
    • 0033761793 scopus 로고    scopus 로고
    • Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
    • Yalman N, Sarper N, Devecioglu O, Anak S, Eryilmaz E, Can M, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr 2000; 42:198-204.
    • (2000) Turk J Pediatr , vol.42 , pp. 198-204
    • Yalman, N.1    Sarper, N.2    Devecioglu, O.3    Anak, S.4    Eryilmaz, E.5    Can, M.6
  • 25
    • 0033017902 scopus 로고    scopus 로고
    • Early allogeneic transplantation for refractory and relapsed acute leukemia following remission induction with FLAG
    • Byrne JL, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D, et al. Early allogeneic transplantation for refractory and relapsed acute leukemia following remission induction with FLAG. Leukemia 1999; 13:786-91.
    • (1999) Leukemia , vol.13 , pp. 786-791
    • Byrne, J.L.1    Dasgupta, E.2    Pallis, M.3    Turzanski, J.4    Forman, K.5    Mitchell, D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.